SPO Global Inc. (OTCMKTS: SPOM) is making another fast move up the charts since dipping below a dime in April. The stock has a history of big moves running from just over a penny to highs of $0.68 per share after the Company announced the definitive merger agreement with Gerpang Healthcare Group of Shandong, China.
Microcapdaily reported on SPOM on February 13 when it gained 600% in one-day stating at the time: SPO Global and Gerpang Healthcare Group (OTCMKTS: SPOM) was up over 600% in afternoon trading after the Company announced it has signed a definitive agreement to acquire Gerpang Healthcare Group of Shandong in a reverse merger agreement. Gerpang has a staff of over 220 people, more than 10 international and national patents, and an annual turnover of approximately RMB 1 billion. This is huge news for SPOM which was liquid and had drifted to $0.0113 lows in recent weeks – the news has transformed SPOM into a fast runner and a volume leader.
SPO Global Inc. (OTC Markets: SPOM) recently completed its merger with Gerpang Healthcare Group. Its subsidiary, Shandong Gerpang Biotechnology Co., Ltd. is an innovative and technological private enterprise located in the pharmaceutical Valley Industrial Park of Jinan high tech Zone. Its main business scope includes biomedical R&D, medical information software development and sales, medical high-tech introduction, medical high-quality consumables production and sales, health care products, drugs, medical equipment consumables agency and sales.
According to its website: GP Healthcare Group is located in Jinan Pharma Valley Industrial Park, High-tech District. It is an innovative technology-based private and high-tech enterprise. The group was founded by School of Pharmaceutical Science of Shandong University Prof. Fengyou Lu. Mr. Lu possesses 24 years of market operating experience in pharmaceutical market in the Greater China region, and has successfully run four foreign-funded enterprises and large private enterprises. The main business scope of the Group includes bio-pharmaceutical R&D, development and sales of medical informatization software, medical high-tech introduction, production and sales of medical quality supplies, dietary supplement, medicine, as well as agents and sales of medical equipment supplies. There are 220 staff. Besides the Group had more than 10 international and national patents, and its annual turnover nearly reaches RMB 1 billion.
To Find out the inside Scoop on SPOM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Back in March SPOM announced a partnership with QingDao Fuyutang Health Development Franchises Ltd. (“Fuyutang Franchise”). Mr. Fengyou Lu, the CEO of SPO Global Inc., and Ms. Jiemei Wang, the Chairman & CEO of Fuyutang Franchises have signed a partnership agreement to set up more than 100 clinics in multiple cities, to build a national wide Fuyutang Chinese Medicine Clinic Franchise in the next two years.
Gerpang Healthcare Group will cooperate with Fuyutang Franchises in Medical terminal services, focusing on technical support, Chinese-Western medical cooperation, physicians advance training, and third-party standardization services to create a standardized medical service management model.
On March 16 SPOM announced On March 15, 2020, Mr. Fengfeng Lu, CEO of SPO Global Inc, visited the headquarters of Lanchuang Technology Ltd., CEO Li Libo introduced the his companys operation , rapid online hospital, standardized pharmacy chain’s easy-to-diagnosis management platform,, and the future development strategy of the Chinese medical market. Lanchuang Technology is willing to participate in the cooperation in the development of Gerpang Healthcare Group Fuyutang Traditional Chinese Medicine Franchises to jointly create an innovative business model of a standardized online platform for medicine. Lanchuang Technology Co., Ltd. is a leading high-tech company with artificial intelligence as its core, product development, production and Internet healthcare operation in China and holds dozens of Chinese and international patents.
— BWALK (@bwalk76) May 11, 2020
According to the last sentence – Gerpang has poured significant resources into bio-pharmeceutical R&D which is now one of the biggest grossing pharma-tech industries in China.
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $64 million market valuation SPOM is virtually debt free with a fairly tight stock structure with Authorized shares at 400 million, and OS at 188 million as of February 27. The new Company Gerpang Healthcare Group of Shandong, China says they have a staff of 220 people, more than 10 international and national patents, and an annual turnover of approximately RMB 1 billion. The stock has quickly attracted a loyal shareholder base that believes this one goes higher. We will be updating on SPOM on a daily basis so make sure you are subscribed to microcapdaily.com so you know what is going on with SPOM.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in SPOM either long or short and we have not been compensated for this article.